New guidelines for the management of multiple sclerosis and neuromyelitis optica were published in Japan in 2017 for doctors and nurses, as well as patients and their family members. They consist of three major parts. The first includes a general discussion regarding the diseases, including brief reviews of seven inflammatory demyelinating diseases of the central nervous system, along with recent advances shown in epidemiological and etiological studies of multiple sclerosis and neuromyelitis optica. That is followed by part I of the detailed discussion section, which describes symptoms, measurements of disability, tests for diagnosis, diagnostic criteria, clinical course and prognosis, and information regarding medical economics and social resources. Finally, part II of the detailed discussion focuses on general treatment strategies, acute stage treatment, disease-modifying therapy and symptomatic treatment for sequelae after relapse. There are 110 clinical questions covered. Physicians and patients are advised to first read chapter 1 in order to understand the current situation regarding related diseases. For treatment of acute stage patients, a common algorithm is proposed. In order to prevent relapse and suppress progression of disability, proper disease-modifying therapy must be chosen for individual patients. Physicians are advised to not jump to the portion where a specific drug is discussed, but rather should first read chapter 13 for unbiased facts regarding the whole body of evidence for disease-modifying therapy. In chapter 11, an escalation therapy strategy starting with baseline drugs is proposed, while induction therapy is mentioned as a possibility for patients with highly active disease.
Introduction
The Japanese guidelines for treatment of multiple sclerosis (MS) were published in 2010, in which MS therapeutics with some consideration of patients with neuromyelitis optica (NMO) and positivity for the anti-aquaporin 4 (AQP4) antibody were focused on. 1 Furthermore, clinical questions (CQs) regarding efficacy, usage and adverse effects were covered for each treatment option, including corticosteroids, plasmapheresis, interferon beta (IFN-b), azathioprine, cyclophosphamide, mitoxantrone and methotrexate. Additional information regarding the revised McDonald criteria 2010, 2 as well as the unsuccessful Japanese clinical trial of intravenous immunoglobulin for prevention of MS relapse and the new oral drug fingolimod, 3 was published online in 2012/2013. 4 Since that time, three additional disease-modifying drugs (DMDs) have become available in Japan, and the position of immunosuppressive drugs for management of MS is no longer as high as before. The new Japanese 2017 guidelines for MS and NMO (MS/NMO guidelines 2017) are intended to be used not only by doctors and nurses, but also patients and their family members. 5 Therefore, the 2017 guidelines provide important information regarding medical and social support resources, measures of disability and treatment outcome, rehabilitation, and symptomatic treatment, in addition to recent advances in epidemiology, pathogenesis and treatments. However, the new oral DMD, dimethyl fumarate, approved for use by the Japanese government at the end of 2016, is not discussed in the new guidelines. It is important to note that appropriate recommendations for individual CQ were proposed when all members of the committee agreed to an assessment to the summary of the body of evidence. Otherwise, answers to CQ are described without recommendation for the purpose of simply providing relevant information. For the convenience of the readers, CQ codes related to important descriptions in the present review article are designated within parentheses.
Overview
In addition to MS and NMO, the 2017 guidelines also present information regarding other inflammatory demyelinating diseases of the central nervous system (CNS), such as Bal o concentric sclerosis, acute disseminated encephalomyelitis (ADEM), acute transverse myelitis, combined central and peripheral demyelination and idiopathic optic neuritis. However, the present body of evidence is insufficient for setting up specific CQ for those disorders, except for MS and NMO, thus in the first chapter only modern concepts and facts related to the remaining five disorders are separately summarized. ADEM might be an initial manifestation of MS, whereas acute transverse myelitis and idiopathic optic neuritis could be followed by the development of MS or NMO. Intravenous methylprednisolone is always the treatment of choice during an acute stage of these disorders, whereas the choice of DMD for prevention of relapse differs between MS and NMO. The clinical courses of ADEM, acute transverse myelitis and idiopathic optic neuritis might be monophasic in affected patients, whereas they can be categorized as clinically isolated syndrome, which is defined as the first acute manifestation of neurological symptom(s) lasting >24 h due to the presence of inflammatory demyelinating lesion(s) in the CNS. Although 30-60% of patients with clinically isolated syndrome might develop clinically definite MS within 5 years, there is no consensus with regard to the timing of starting a DMD at this stage (CQ7-1-3). Furthermore, as evidence for the use of therapeutics in cases of primary progressive MS (PPMS) is scant, most of the recommendations and answers presented are in regard to relapsing-remitting MS (RRMS). Chapter 1 of the guidelines, which is not long and will not require a long time to read, is concise and helpful to understand the present status of inflammatory demyelinating diseases of the CNS.
Immunopathogenesis of MS and NMO

Genetic risk factors
It is important to understand genetic and environmental factors underlying the immunopathogeneses of MS and NMO, as these two disorders are not fully discussed in a separate manner in the previous guidelines. In Japanese individuals, the genes reported to be risk factors for MS are HLA-DRB1*15:01, HLA-DRB1*04:05 and interleukin-7 receptor-a (IL7A; CQ3-2-1), whereas those for NMO are HLA-DPB1*05:01 and HLA-DRB1*16:02 (CQ3-2-3). Reported findings show that immunity is closely related to the pathogenesis of each disorder. However, additional studies are necessary to confirm differences in genetic factors between MS and NMO, because of the relatively small sample sizes and heterogeneity of patients in previous studies of NMO.
Environmental risk factors
Various infectious agents have been reported to be environmental risk factors for development of MS. Among those, there is firm evidence showing that Epstein-Barr virus infection is closely associated (CQ3-3-1), whereas other factors include the latitude of the residential area, concentration of vitamin D in serum and smoking habit (CQ3-4-1). There was a preceding infection in 15-20% of patients with NMO, though no contribution of a specific virus to the pathogenesis has been reported (CQ3-3-2). Latitude might also be a risk factor for NMO in Japan and ADEM in Western countries (CQ3-4-2).
Immunological mechanism
Autoimmunity against protein components of the myelin sheath and/or oligodendrocytes in the CNS has been implicated in MS. Although molecular mimicry between myelin antigen and a portion of infectious agents could initiate autoimmune responses in MS, the first targeted antigen in the early stage of the disease has not been identified. As inferred from results obtained in studies of experimental autoimmune encephalomyelitis, myelin antigen-specific type 1 helper T cells and specific type 17 helper T cells, which produce the pro-inflammatory cytokines IFN-c and interleukin (IL)-17, respectively, become activated in peripheral lymphoid tissue. Those pathogenic T cells are then able to invade the CNS through vascular endothelium forming the blood-brain barrier. They become re-activated by interaction with antigen-presenting cells in the CNS, including microglia and dendritic cells, and further propagate inflammatory processes leading to demyelination (CQ3-1-1).
There have been several discussions regarding whether MS and NMO are mutually exclusive distinct disease entities. The new guidelines do not present any conclusive point of view in this regard, and evidence for both disorders accumulated up to September 2016 is equally discussed. Along this line, the presence of the anti-AQP4 antibody is a hallmark of NMO, and exists in circulation but not in cerebrospinal fluid (CSF). However, once penetration of the blood-brain barrier is achieved, anti-AQP4 antibodies gain access to AQP4 molecules expressed on the surface of astrocytes and render astrocyte cytotoxicity through activation of the complement system. Neutrophils, eosinophils and macrophages might be involved in antibody-dependent cell-mediated cytotoxicity against astrocytes. Also, IL-6 has a key role in activating plasmablasts, which in turn enhance production of anti-AQP4 antibodies (CQ3-1-2). Recently, it was proposed that patients positive for the anti-AQP4 antibody should be categorized as having a seropositive NMO spectrum disorder (NMOSD), irrespective of their neurological symptoms (CQ7-2). 6 This concept is very practical, leading physicians to use corticosteroids and immunosuppressive drugs for suppression of NMO/ NMOSD.
Pathology of lesion development
Pathological studies of lesions in affected patients are helpful to understand immunological targets and immune effector components, which are involved in the disease pathogenesis at various stages. The primary feature of an MS lesion is inflammatory demyelination in the brain and spinal cord, and the affected site consists of T cells, macrophages, B cells and plasma cells, which form perivascular cuffing. The composite of myelin debris will change during the course of acute demyelination. Myelin breakdown starts from minor myelin, comprised of myelin-associated glycoprotein and myelin oligodendrocyte glycoprotein, and extends to major myelin that contains myelin basic protein and proteolipid protein. In acute demyelinating lesions, there are also remyelinated lesions as well as axonal damage to some extent. It is important to note that an axonal pathology is not uncommon in the CNS, even in early-stage MS patients. Gliosis rendered by fibrous astrocytes is a feature of chronic-stage demyelinating lesions. In contrast to the aforementioned lesions of RRMS, those of PPMS are characterized by degeneration of oligodendrocytes (CQ3-5-1).
Typical early NMO lesions show perivascular deposition of activated complements and immunoglobulins, hyalinized blood vessels, infiltration of inflammatory cells including neutrophils, loss of AQP4 extending over the site of demyelination, and astrocyte dystrophy. Findings of late-stage lesions are demyelination, necrosis and severe axonal damage. It should be emphasized that demyelination does not occur in the cerebral cortex in NMO, whereas cortical demyelination is a feature of MS (CQ3-5-2). It is now widely accepted that the anti-AQP4 antibody has a pivotal role in initiation of the first immunological event, which is followed by activation of the complement system and then infiltration by inflammatory cells. The fact that autoantibodies and complements; that is, humoral immunity, trigger pathological processes leading to CNS damage in NMO makes its treatment strategy quite different than that of MS, as cellular immunity plays a central role in the latter.
Diagnosis of MS and NMO
A correct diagnosis is mandatory in order to choose among treatment options. The recent trend is to start treatment as early as possible after diagnosis, because it is known that irreversible axonal damage begins in the early stage of the disease, and disease activity 5 to 10-fold more frequent than that recognized as clinical relapse is detected by magnetic resonance imaging (MRI; CQ6-1-1). In this regard, the concept of no evidence of disease activity-4 has been proposed as an ideal outcome measure for treatment of MS, with no evidence of disease activity-4 defined more specifically as no evidence of clinical relapse, disease activity by MRI, brain atrophy and progression of disability. As for NMO, the annualized relapse rate, determined based on the frequency of clinical manifestation of acute episodes in 1 year, is useful for measurement of treatment outcome (CQ10-1-1).
Symptoms and signs
Neurological symptoms and signs suggestive of MS vary depending on the site of inflammatory lesions, though they are always an important clue for the first step of diagnosis. Considering that MS is a disease of the CNS white matter, headache, seizures and extrapyramidal signs will be red flags against the diagnosis of MS. It should also be noted that cognitive impairment and psychiatric symptoms are common (>50%) during the course of MS (CQ4-1). In contrast, the presence of altitudinal scotoma, near loss of vision, intractable hiccups and nausea lasting for >24 h, as well as narcolepsy and inappropriate secretion of antidiuretic hormones, favor a diagnosis of NMO (CQ4-2). Lhermitte's sign, painful tonic spasm and Uhthoff's phenomenon are found in both disorders. Uhthoff's phenomenon is a transient worsening of neurological symptoms, such as visual acuity as a result of elevation of body temperature, that is derived from transient conduction delay or block in the previously demyelinated area, which disappears with cooling. As true relapse will cause symptoms lasting for >24 h without fever or infection, patients and physicians should be aware of this transient phenomenon to avoid unnecessary treatment (CQ4-4).
Assessment of disability
Measurement of disability as a result of neurological impairment in patients with MS and NMO is strongly recommended by use of the Kurtzke Expanded Disability Status Scale. Furthermore, quality of life (QOL) in patients with MS can be assessed using the Japanese version of Functional Assessment of MS or the MS Quality of Life Questionnaire-54. For determining QOL in patients with NMO, the Brief Pain Inventory and Short Form 36-item can be used (CQ5-1). In addition, the Brief Repeatable Battery of Neuropsychological tests are able to assess cognitive function in patients with MS as well as those with NMO (CQ5-2).
Diagnostic criteria
The McDonald criteria, revised in 2010, 2 are generally used internationally for diagnosis of MS, whereas the MS/NMO 2017 guidelines recommend use of the Japanese diagnostic criteria, which were modified from the 2010 McDonald criteria and presented in 2015 by the Committee of Neuroimmunological Diseases for the Ministry of Health, Labor and Welfare of Japan (CQ7-1-1; Table 1 ). As for NMO, the new MS/NMO 2017 guidelines recommend the 2006 version of the diagnostic criteria (CQ7-2; Table 2 ). 7 The 2015 version, which uses a broader concept of illness in terms of anti-AQP4 antibody positivity, can be used for diagnosis of NMOSD. 6 It is important to note that MS and NMO/NMOSD require cautious differential diagnosis, including malignancy, as well as the presence of syphilis, cerebrovascular disease, cervical spondylotic myelopathy, syringomyelia, spinocerebellar degeneration, human T-cell leukemia virus-1 associated myelopathy, collagen/vascular disease, Sj€ ogren's syndrome, neuroBehc ßet's disease, neurosarcoidosis, mitochondrial encephalomyopathy and progressive multifocal leukoencephalopathy (CQ7-1-2).
Diagnostic procedures
MRI MRI is a powerful tool for defining both dissemination in space and dissemination in time of inflammatory demyelinating CNS lesions. T2-weighted imaging can visualize the site of acute inflammation, edema and demyelination, whereas a fluid-attenuated inversion recovery method is useful for detecting periventricular and subcortical lesions. Short T1 inversion recovery images have an advantage for diagnosing acute optic neuritis. T1-weighted images show lesions related to axonal damage as a T1 black hole, whereas gadolinium-enhanced lesions and newly developed or enlarging lesions shown by T2 show ongoing active disease (CQ6-1-2). According to the current diagnostic criteria, a single MRI examination of the brain can simultaneously verify dissemination in space and dissemination in time. The presence of T2-high lesions extending over three vertebral segments in the spinal cord, as well as edematous findings along more than half of the portion of the entire optic nerve, are suggestive of NMO (CQ6-1-3).
Neurophysiological examinations
Neurophysiological findings, including visual evoked potential, auditory brainstem response, somatosensory evoked potential and motor evoked potential, still have validity for elucidating subclinical demyelinating lesions that cannot be visualized by MRI; that is, dissemination in space. Those tests can show the presence of demyelination along the tract of nerve impulses, as conduction delay occurs at a site of demyelination. Visual evoked potential and somatosensory evoked potential yield abnormal results more often in patients with PPMS (approximately 70%) than in those with RRMS (<50%; CQ6-4-1, CQ6-4-2).
Ophthalmic examinations are necessary even in asymptomatic patients, as visual pathways are frequently involved in MS and NMO. It is recommended to carry out checks of visual acuity, visual field and optic fundi. Optical coherence tomography is used for assessment of demyelination and axonal damage in the retinal nerve fiber layer, whereas critical flicker frequency is useful for detecting early optic nerve dysfunction during acute relapse (CQ6-5).
CSF and blood
Examinations of the CSF are highly recommended in the clinical setting of inflammatory demyelinating diseases of the CNS including MS and NMO (CQ6-3-1). For diagnosis of MS, increased immunoglobulin G (IgG) index level, which is calculated using the following formula (CSF IgG/serum IgG divided by CSF albumin/serum albumin), and positive oligoclonal IgG bands are supportive findings. An elevated myelin basic protein level suggests ongoing demyelination in the CNS, which is especially associated with MS and ADEM, whereas an elevated CSF level of glial fibrillary acidic protein facilitates a diagnosis of NMO. Other features of CSF samples obtained from patients with NMO are known to be elevated numbers of white blood cells (>50/lL) containing neutrophils and elevated levels of IL-6 during acute exacerbation of the disease (CQ6-3-2).
In terms of blood tests, those findings do not contribute greatly to diagnosis except for the anti-AQP4 antibody in serum for NMO/NMOSD. There is no specific test for MS. Evidence of the antineurofascin 155 antibody in serum might be helpful for diagnosing combined central and peripheral demyelination, whereas a high serum semaphoring 4A level could predict a suboptimal response to IFN-b therapy in MS. In contrast, serological testing for the anti-John Cunningham virus antibody and anti-varicella zoster virus antibody is strongly recommended before starting treatment with natalizumab or fingolimod, respectively (CQ6-2).
Clinical course, and prognosis of MS and NMO patients
No nationwide study of the natural course of MS has been carried out in Japan. In light of such studies carried out in Western countries, 80-90% of patients with MS show a relapsing-remitting course (RRMS), while the remaining 10-20% have a chronic progressive course (PPMS; CQ8-1-2). The average age of disease onset in RRMS is approximately 30 years. Although RRMS patients often recover from clinical relapse without neurological sequelae during the early stage of the disease, neurological impairment gradually accumulates over time. Furthermore, 50% of these patients come to show a progressive course without apparent clinical relapse at 15-20 years after onset (secondary progressive MS). Some investigators have emphasized that once an MS patient reaches an Expanded Disability Status Scale score of 3, they will thereafter suffer from a steady progression of disability. As for PPMS, the average age of onset is approximately 40 years. Spinal cord atrophy is conspicuous early in the course. Also, disability progression is known to be faster in PPMS as compared with RRMS, with the mean period to use of a wheelchair reported to be 13.4 and 33.1 years, respectively. However, the number of PPMS patients in Japan seems to be fewer (5%) than in Western countries. Likewise, the rate of transition from RRMS to secondary progressive MS might be lower among Japanese patients with MS. In contrast to MS, patients with NMO show stepwise deterioration of neurological disability even in an early stage of the disease, as each relapse tends to be severe and resistant to intravenous methylprednisolone treatment, therefore causing serious sequelae (CQ8-2). It is possible that a single attack will result in loss of vision and wheelchair-bound status, whereas a chronic progressive course of NMO is rare.
Considering the above-mentioned prognostic factors for both disorders, it is important for physicians to prepare an individual treatment plan for each patient that is based on a correct diagnosis.
Treatment strategy
Treatment for MS and NMO patients should be planned for the purpose of coping with three major aspects of illness; that is, acute exacerbation of neurological symptoms (clinical relapse), chronic asymptomatic stage (remission) and an annoying period of residual neurological impairment.
After diagnosis, early introduction of disease-modifying therapy (DMT) is strongly recommended for patients with RRMS, as irreversible lesions increase over time. DMT can be used for patients with secondary progressive MS if clinical relapse occurs or disease activity is shown in MRI results, though use of a DMD for clinically isolated syndrome remains controversial (CQ10-2-1). Similarly, it is strongly recommended to start treatment with corticosteroids for anti-AQP4 antibody-positive as well as seronegative NMO patients, because of the severity of relapse (CQ10-2-2). The primary goal of treatment is to achieve a disease activity-free status, thus a remission phase should be maintained for as long as possible, hopefully for the full course of life. In this respect, the most suitable DMD must be carefully chosen for patients with MS in the light of efficacy, safety, adherence and tolerability. Physicians also should take into account individual patient age, sex, socioeconomic status, complications and disease activity (CQ11-2). For maintenance of remission in patients with NMO, oral prednisolone (2.5-20 mg/ day) is recommended with or without combined azathioprine therapy (>2 mg/kg/day). Mycophenolate mofetil, mitoxantrone, cyclosporine A (CyA) and tacrolimus can also be used. However, a serious concern is that DMD used for prevention of MS IgG, immunoglobulin G; MRI, magnetic resonance imaging; NMO, neuromyelitis optica.
relapse, including IFN-b, fingolimod and natalizumab, can potentially increase the relapse rate or trigger a serious relapse in patients with NMO (CQ11-3).
Despite continued DMT, some patients suffer from acute exacerbations of the disease. Presently, physicians should consider two different medical approaches: (i) settle ongoing inflammation; and (ii) judge the efficacy of the present treatment. Although there are no standardized criteria for recognition of a suboptimal responder or nonresponder to a particular DMD, its effectiveness can be assessed by use of the annualized relapse rate, progression of disability and change in MRI findings within 1 year of treatment (CQ10-3-1) . When the patient is regarded as a non-responder to a particular DMD, the new guidelines strongly recommended switching to another DMD (CQ10-3-2).
Acute disease relapse should be treated as soon as possible. However, when there are residual symptoms that have effects on activities of daily living, symptomatic treatments might be necessary and information regarding those is provided in chapter 14 of the new guidelines.
Treatment during acute relapse
For acute manifestation of neurological symptoms as a result of inflammatory demyelinating diseases of the CNS, listed in chapter 1 of the new guidelines, steroid pulse therapy with intravenous methylprednisolone (>500 mg/day) for 3-5 days is the first choice of treatment (CQ12-1-1, CQ12-1-2 ). This therapy might be repeated once or twice for patients with MS, and plasmapheresis (PP) should be considered if substantial improvement is not obtained (CQ11-1). For patients with NMO and ADEM, it is recommended to not continue repeated steroid pulse therapy, but rather to start PP earlier. Regarding the method of PP, firm evidence has been shown regarding the effectiveness of plasma exchange, whereas immunoadsorption plasmapheresis can also be used (CQ12-2-1, CQ12-2-2). Intravenous immunoglobulin therapy is another potential option for acute- stage NMO. The 2017 MS/NMO guidelines include a proposal for a common algorithm for treatment of an acute stage of inflammatory demyelinating diseases of the CNS (CQ11-1; Fig. 1 ).
How to control disease activity in MS and NMO patients
There are now six candidate DMD, including IFNb1b, IFN-b1a, fingolimod, natalizumab, glatiramer acetate and dimethyl fumarate (listed in their order of appearance in the Japanese market), for a physician to choose from as treatment for a particular patient with RRMS. Careful consideration of the balance between the merits and demerits of a drug in accordance with patient disease activity and QOL must be made. In terms of effectiveness and longterm safety, treatment is generally started with a baseline drug, such as IFN-b1b, IFN-b1a or glatiramer acetate, which are injectable. When the first chosen DMD is judged to be ineffective, that should be substituted with another baseline drug, or switched to a second-line (fingolimod or natalizumab for anti-John Cunningham virus antibodynegative patients) or third-line (natalizumab for anti-John Cunningham virus antibody-positive patients) option. This type of stepwise use of DMD, in which safety risk increases with stronger potency for suppression of MS disease activity, is termed escalation therapy (CQ11-2). Features of these five drugs are summarized in Table 3 . Recommendations for the newly released dimethyl fumarate, an oral drug, are awaiting reports of clinical experiences in Japan. As for NMO, no specific drug has a primary position for controlling disease activity. If initial treatment fails, dosage increase or change to another drug should be considered (CQ11-3).
It must be noted that some MS patients show high disease activity from the earliest stage. As the window of opportunity for a DMT to exert sufficient effects can be narrow for such patients, escalation therapy might cause loss of precious time for treatment. Therefore, induction therapy starting with a second-or third-line drug might be necessary for active MS patients (CQ11-2). If the following conditions are found in a patient with MS, there is a possibility of highly active disease, indicated by more than two clinical relapses within the previous 12 months, two separate MRI scans showing more than a few gadolinium enhancing lesions and/or new or enlarging T2 lesions, and fast progression of the Expanded Disability Status Scale score (CQ13-2-3).
How to use DMD
In this part, detailed usage of specific drugs is not noted, as such information is systematically provided in the 2017 guidelines in chapter 13, entitled "Treatment for Prevention of Relapse and Suppression of Progression", which appears in part II of the detailed discussion section. In that chapter, the same structure of CQ is used for each drug; that is, efficacy for preventing relapse, efficacy for suppressing progression of disability, how to use and adverse effects. The drugs discussed in detail there are IFN-b (CQ13-1-1, CQ13-1-2, CQ13-1-3, CQ13-1-4), fingolimod (CQ13-2-1, CQ13-2-2, CQ13-2-3, CQ13-2-4), natalizumab (CQ13-3-1, CQ13-3-2, CQ13-3-3, CQ13-3-4), glatiramer acetate (CQ13-4-1, CQ13-4-2, CQ13-4-3, CQ13-4-4) and corticosteroids (CQ13-5-1, CQ13-5-2, CQ13-5-3). Furthermore, detailed information regarding immunosuppressive drugs, including azathioprine, cyclophosphamide, mitoxantrone, methotrexate, mycophenolate mofetil, tacrolimus and cyclosporine A (CQ13-6-1, CQ13-6-2, CQ13-6-3, CQ13-6-4), is summarized. In the new guidelines, physicians are advised to first skim over chapter 13 to obtain unbiased notions regarding the whole body of evidence for DMT, which will be of a great help when selecting from among the treatment options for individual patients.
Symptomatic treatments
The 2017 MS/NMO guidelines attempt to recommend available treatments for eight annoying symptoms appearing as sequelae after relapse, though the general body of evidence for those is weak. For spasticity, rehabilitation can help to improve it, whereas a focal injection of botulinum toxin and intrathecal baclofen therapy can be used for severe symptoms (CQ14-1). Pain and abnormal sensations often have effects on patient QOL. For alleviating such symptoms, antidepressants including tricyclic antidepressants, selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors might be helpful, whereas anti-epileptic drugs, such as gabapentin and pregabalin, might also be effective (CQ14-2). Urinary disturbance as a result of an overactive bladder might be improved by administration of an anticholinergic drug, including oxybutynin and solifenacin. For an atonic bladder, manual compression of the bladder and a-blocking drugs could have an effect, though intermittent catheterization or use of an indwelling catheter might be necessary for a serious disturbance (CQ14-3). Sexual difficulties in patients with MS have not been investigated in Japan. Nevertheless, the new guidelines recommended use of sildenafil, vardenafil and tadalafil for erectile dysfunction, whereas estrogen cream can be used for vaginal lubrication by female patients (CQ14-4). Although not commonly described, fatigue or lassitude is one of the most disabling symptoms experienced by MS and NMO patients. To cope, rehabilitation is recommended, while amantadine and carnitine can also be given (CQ14-5). Psychiatric symptoms are also common in MS. Depression has effects on QOL, and can be treated using antidepressants and cognitive behavioral therapy, whereas amitriptyline or dextromethorphan/quinidine can be given for emotional incontinence (CQ14-6). Recently, cognitive dysfunction has been reported to begin early during the course of illness, and it is strongly recommended to use intradermal IFN-b1b, intramuscular IFN-b1a or intravenous drip infusion of natalizumab to avoid progressive deterioration. In contrast, donepezil, memantine, rivastigmine and ginkgo biloba leaves were not found to be effective for improvement of cognitive decline in MS (CQ14-7). The brainstem is sometimes involved in an acute relapse of MS or NMO, with diplopia remaining and seriously affecting QOL. Prism glasses can help to improve vision. Furthermore, administration of 4-aminopyridine might be chosen for downbeat nystagmus, whereas memantine or gabapentin can be used for alleviating oscillopsia (CQ14-8).
Conclusion
The 2017 MS/NMO guidelines are an attempt to provide physicians, as well as patients and their family members, with the latest information regarding basic, epidemiological and clinical aspects of inflammatory demyelinating diseases of the CNS, including established evidence in regard to MS and accumulating evidence for NMO. Nevertheless, the guidelines lack information regarding the newly developed DMD, dimethyl fumarate, for MS, and there is also no direct reflection of opinions from patients or family members. It is anticipated that future guidelines will consider these shortcomings. Advances in the field of neuroimmunology continue at a rapid pace, thus the present situations might change within a few years. Therefore, the reader is advised not to place this guideline book high on a shelf, but rather in an easily accessed location so as to add new information as a memorandum when it becomes available.
